6325 – Hyperinfection syndrome or disseminated strongyloidiasis

DBQ: Link to Index of DBQ/Exams by Disabilitiy for DC 6325

Definition

Hyperinfection syndrome and disseminated strongyloidiasis are severe, potentially life-threatening complications of a Strongyloides stercoralis infection, particularly in individuals with weakened immune systems. Hyperinfection syndrome is characterized by an uncontrolled increase in the number of larvae within the body, primarily affecting the gastrointestinal and respiratory tracts. Disseminated strongyloidiasis, on the other hand, involves the migration of larvae to organs outside the typical life cycle, such as the brain, liver, or heart. Both conditions can lead to serious complications and even death if not promptly diagnosed and treated. 

Etiology

Hyperinfection syndrome and disseminated strongyloidiasis, caused by the parasitic nematode Strongyloides stercoralis, are typically triggered by immunosuppression, particularly corticosteroid use. This leads to an overwhelming increase in parasite burden due to accelerated autoinfection and potential spread to other organs. 

• Corticosteroids: The most common trigger is the use of corticosteroids, even in short courses or at low doses, for conditions like asthma or COPD exacerbations. 
• Other Immunosuppressive Therapies: Other immunosuppressive drugs, such as those used in organ transplantation or for certain autoimmune diseases, can also increase the risk. 
• Underlying Immunosuppressive Conditions: Conditions like HIV infection (especially in later stages), certain cancers, and malnutrition can also predispose individuals to hyperinfection. 
• Human T-lymphotropic virus 1 (HTLV-1) infection: This virus can also impair immune function and increase the risk. 
• Alcohol Use Disorder: Alcohol use disorder has also been associated with hyperinfection. 
• Impaired Immune Response: The underlying mechanism involves a breakdown in the body's immune defenses, particularly Th2 cell-mediated immunity and humoral immunity, which normally control the parasite. 

Signs & Symptoms

In the context of strongyloidiasis, hyperinfection syndrome and disseminated strongyloidiasis represent severe, potentially life-threatening conditions resulting from the uncontrolled replication and spread of the Strongyloides stercoralis parasite. These conditions are particularly prevalent in individuals with compromised immune systems, such as those receiving corticosteroids or with co-infection with HTLV-1. 

Key signs and symptoms

• Exacerbated Gastrointestinal Symptoms: Symptoms like abdominal pain, nausea, vomiting, and diarrhea become more severe and may include complications such as:
  • Ileus (intestinal paralysis)
  • Intestinal obstruction
  • Mucosal ulceration and hemorrhage (bleeding)
  • Peritonitis (inflammation of the abdominal lining)
• Worsened Pulmonary Symptoms: Cough and wheezing become more pronounced, potentially progressing to:
  • Pneumonitis (inflammation of the lungs)
  • Hemoptysis (coughing up blood)
  • Respiratory failure
• Neurological Manifestations: Larvae can invade the central nervous system, leading to:
  • Aseptic or gram-negative meningitis (inflammation of the membranes surrounding the brain and spinal cord)
  • Brain abscess
  • Altered mental status or even coma
• Systemic Involvement: Beyond the typical sites of infection (skin, gastrointestinal tract, and lungs), disseminated disease involves the spread of larvae to other organs, such as:
  • Liver
  • Heart
  • Kidneys
  • Lymph nodes
  • Pancreas
• Secondary Infections: Disruption of the intestinal lining by migrating larvae can lead to the entry of enteric bacteria into the bloodstream, causing:
  • Gram-negative bacteremia or sepsis (life-threatening blood infection)
  • Meningitis
  • Endocarditis (inflammation of the inner lining of the heart)
• Cutaneous Manifestations: Recurrent rashes, particularly larva currens (rapidly migrating, serpiginous rash), may be observed. In severe cases, a rapidly progressive, diffuse, petechial purpuric eruption can occur.

Tests

For diagnosing Strongyloides hyperinfection syndrome or disseminated strongyloidiasis, various tests can be used, and often a combination of approaches is necessary. Here's a breakdown: 

1. Stool examination

• Microscopy and Culture for Ova and Parasites (O&P): Microscopic identification of Strongyloides stercoralis larvae in stool is the definitive diagnostic test.
  • Direct wet mounts: Have a very low yield.
  • Concentration methods: Increase sensitivity, such as Baermann concentration, Horadi-Mori filter paper culture, quantitative acetate concentration technique, and nutrient agar plate cultures.
  • Agar plate method: Considered the most sensitive and efficient method for detecting larvae that crawl out of the stool.
  • Limitations: Larvae excretion can be intermittent and in low numbers, so multiple stool examinations (at least 3, up to 7) are often needed to reach acceptable sensitivity. 

2. Serology

• Enzyme Immunoassay (EIA/ELISA) for IgG antibodies: Detects anti-Strongyloides antibodies in the serum and is the most common serological test.
  • Sensitivity: High, especially for chronic infections (around 85-90%).
  • Specificity: May be compromised by cross-reactions with other helminthic infections.
  • Limitations: Cannot distinguish between past and current infection, and sensitivity can be lower in severely immunocompromised patients. 

3. Molecular tests

• Polymerase Chain Reaction (PCR): Can detect S. stercoralis DNA in stool samples, offering improved sensitivity and specificity compared to microscopy.
  • Limitations: Not universally available and can be expensive. 

4. Other diagnostics (especially for hyperinfection/disseminated disease)

• Duodenal aspirate or biopsy: Can reveal parasites that have infiltrated duodenal glands, gastric crypts, or the lamina propria, particularly useful when stool examinations are negative or Strongyloides colitis is suspected.
• Entero-test (string test): A less invasive method for examining duodenal fluid for larvae.
• Sputum and Bronchoalveolar Lavage (BAL): In hyperinfection/disseminated disease, larvae can be found in sputum or BAL fluid.
• Cerebrospinal Fluid (CSF): May reveal larvae in cases of meningitis, according to the National Institutes of Health (NIH).
• Skin biopsy: In severe cases, larvae may be observed in the dermis. 

Considerations for diagnosis

• Immunocompromised patients: May have lower sensitivity to serologic tests and may require more aggressive diagnostic approaches.
• Eosinophilia: While a marker of acute infection, eosinophilia may be absent in patients with hyperinfection syndrome or disseminated disease.
• History of travel or residence in endemic areas: Important risk factors for strongyloidiasis. 

Treatment

Hyperinfection syndrome and disseminated strongyloidiasis are severe forms of Strongyloides infection, often life-threatening, particularly in immunocompromised individuals. Treatment is crucial and involves a multi-pronged approach focused on eradicating the parasite and supporting the patient. 

Key treatment components

1. Antiparasitic medication:
   • Ivermectin: This is the drug of choice, recommended at 200 μg/kg daily.
   • Albendazole: May be used as an alternative or in combination with ivermectin, especially in areas with other parasitic co-infections.
   • Duration: Treatment should continue until the parasite is no longer detectable in clinical specimens (stool and/or sputum) for at least two weeks. Repeated or prolonged courses may be necessary.
2. Reduce or discontinue immunosuppressants: If the patient is on corticosteroids or other immunosuppressive drugs, these should be tapered or stopped, if possible, under medical guidance. This is crucial as immunosuppression can fuel the hyperinfection.
3. Supportive care:
   • Broad-spectrum antibiotics: Treat concurrent bacterial infections, especially if there's evidence of sepsis or meningitis caused by enteric pathogens.
   • Manage complications: Provide intravenous fluids, blood transfusions, mechanical ventilation, or other interventions as needed to address complications like hemorrhage, respiratory failure, or organ dysfunction.
   • Symptom management: Antihistamines for skin reactions, inhaled bronchodilators for wheezing (avoiding corticosteroids).
4. Alternative administration routes: For patients unable to tolerate oral medication (due to malabsorption, ileus, etc.), rectal administration of ivermectin can be considered. In extreme cases, and after obtaining appropriate approvals, the veterinary subcutaneous formulation of ivermectin has been used.

Residuals

Strongyloidiasis, caused by the parasite Strongyloides stercoralis, can lead to severe and potentially fatal conditions like hyperinfection syndrome and disseminated strongyloidiasis, especially in immunocompromised individuals. While treatment aims for complete eradication of the parasite, some individuals may experience persistent or recurrent issues even after the initial infection is cleared. 

Possible residual effects

• Chronic Strongyloidiasis: Individuals might have experienced chronic symptoms before or after hyperinfection, such as gastrointestinal problems (abdominal pain, diarrhea, constipation) or skin rashes (urticaria or larva currens), according to the CDC. These can persist or recur intermittently, requiring ongoing monitoring and potentially further treatment.
• Organ Damage: Disseminated strongyloidiasis can affect various organs, including the lungs, liver, brain, heart, and urinary tract. Damage to these organs can lead to lasting complications such as:
  • Pulmonary issues: Chronic cough, wheezing, pneumonitis, or respiratory failure.
  • Gastrointestinal problems: Ileus, bowel obstruction, malabsorption, or ongoing digestive issues.
  • Neurological problems: Meningitis or other CNS manifestations, potentially leading to long-term neurological impairments.
  • Other: Renal dysfunction, arthritis, cardiac arrhythmias, or chronic malabsorption.
• Recurrent Infection: Even after treatment, autoinfection (where larvae within the body reinfect the host) can occur, potentially leading to recurrence of symptoms or requiring repeat courses of treatment. 

Monitoring and management

• Follow-up: Regular follow-up with healthcare providers is essential, especially for individuals who were immunocompromised, to monitor for recurrent infection or residual symptoms.
• Test of Cure: While there isn't a single definitive test of cure, repeated stool examinations or serology can be used to assess the effectiveness of treatment and confirm parasitic clearance.
• Treating Persistent Symptoms: If symptoms persist after treatment, further evaluation is needed to differentiate between potential residual effects of the infection and other possible underlying conditions.
• Secondary Prophylaxis: In some cases, particularly in immunocompromised individuals with a history of severe strongyloidiasis, periodic repeat courses of treatment might be considered to prevent future complications, according to Infectious Disease Advisor.